FDA Approves METFORMIN HYDROCHLORIDE — Ajanta Pharma USA Inc.

Ajanta Pharma USA Inc. has announced the FDA approval of its abbreviated new drug application (ANDA213651) for Metformin Hydrochloride, representing a competitive entry into the widely trafficked generic market for this widely prescribed antidiabetic therapy. While the market impact is expected to be primarily incremental to the existing roster of generic competitors, the entry of another manufacturer serves to sustain an already saturated landscape with ample product availability to serve managed care and pharmacy benefit management networks.